Director, Precision Medicine

Stacey Gilbert, MPH, MBA

As the director of Precision Medicine, Stacey brings nearly 26 years of life sciences experience to ADVI after serving in remote and corporate-based roles spanning sales, sales leadership, learning/development, market access contracting/strategy, pricing, coding, and reimbursement, outcomes research, access marketing, and product commercialization across pharmaceutical, medical device, and molecular diagnostics arenas.
Stacey holds a BS in Textile Product Marketing from the University of North Carolina at Greensboro. She received her MBA with a concentration on healthcare administration and Master of Public Health with a concentration on community health from Baylor University in Waco, TX.

CEO insights

Real analysis from people who’ve been there

Explore all CEO insights

Why Clinical Laboratories Should Consider Weighing In on CMS and CDC’s New CLIA Request for Information

An opportunity for laboratories to help shape the future of CLIA regulation On July 16, 2026, the Centers for Medicare …

Stacey Gilbert, MPH, MBA
July 27, 2026

Precision Medicine

Test Ordering Simplification Will Not Be Optional in the Near Future: Why Labs Must Act Before May 26, 2028

The Centers for Medicare & Medicaid Services’ (CMS) Administrative Simplification: Adoption of Standards for Health Care Claims Attachments Transactions and …

Stacey Gilbert, MPH, MBA
May 11, 2026

Precision Medicine

The MolDX Technical Assessment: How to Move Your Test from “Not Successful” to Medicare Coverage Success

In the laboratory space, the MolDX Technical Assessment (TA) is often the moment where the gap between “a great test” …

Stacey Gilbert, MPH, MBA
April 9, 2026

Precision Medicine

CRUSH and Genetic and Molecular Laboratories: A Potential Shift in Medicare Oversight

Genetic, molecular, and reference laboratories are closely watching a new Medicare concept known as CRUSH- short for Comprehensive Regulations to …

Stacey Gilbert, MPH, MBA
March 17, 2026

Oncology/biologics Precision Medicine

March Is Colorectal Cancer Awareness Month: Why CMS’s Proposed NCD 210.3 Update Could Accelerate Patient‑Centered Screening Access

Colorectal cancer (CRC) screening saves lives, but only when patients are able to access care in a way that meets …

Stacey Gilbert, MPH, MBA
March 17, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Precision Medicine

A New Era for Cancer Detection Begins with the Sewell MCED Law

We are seeing a long‑anticipated and important policy inflection point.  By now you might have heard that Congress passed the …

Stacey Gilbert, MPH, MBA
February 11, 2026

Precision Medicine

FDA Proposes Down-Classification of Oncology Companion Diagnostics: A Q&A on Precision Medicine

The Food and Drug Administration (FDA) has announced a significant proposed change affecting oncology companion diagnostics (CDx) that could streamline …

Stacey Gilbert, MPH, MBA
December 16, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.

Start now.